Liver Cancer Clinical Trials

• Locally advanced or metastatic and/or unresectable HCC

• WHO/ECOG performance status of 0 or 1

• BCLC stage B (that is not eligible for locoregional therapy) or stage C.

• Child-Pugh Score class A

• At least one measurable target lesion

• Participants with active HBV infection must receive antiviral therapy for a minimum of 14 days prior to randomization to show evidence of HBV stabilization or signs of viral response.

• Participants with active HCV infection must be well controlled. Participants co-infected with HBV and HCV are not eligible.

• Adequate organ and bone marrow function measured during the screening period.

• Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.

• Disease that is not amenable to curative surgical and/or locoregional therapies. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.